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Abstract  18 
High levels of undiagnosed and untreated HCV infection exist in prison populations globally. Prisons are a 19 
key location to identify, treat and prevent HCV infection among people who inject drugs (PWID). 20 
Understanding prisoners’ lived experiences of the HCV continuum of care informs how HCV care can be 21 
effectively delivered to this marginalised and high-risk population. This study aimed to explore Irish 22 
prisoners’ experience of prison and community-based HCV care. We conducted one-to-one interviews with 23 
25 male prisoners with chronic HCV infection. Data collection and analysis was informed by grounded 24 
theory. The mean age of participants and first incarceration was 39.5 and 18.3 years respectively. The mean 25 
number of incarcerations was eight. The following themes were identified: medical and social factors 26 
influencing engagement (fear of treatment and lack of knowledge, HCV relevance and competing 27 
priorities), adverse impact of HCV on health and wellness, positive experience of prison life and health care 28 
and the transformative clinical and non-clinical changes associated with HCV treatment and cure. Findings 29 
suggest that prison release was associated with multiple stressors including homelessness and drug 30 
dependence which quickly eroded the health benefits gained during incarceration. The study generated a 31 
substantive theory of the need to increase the importance of HCV care among the routine competing 32 
priorities associated with the lives of PWID. HCV infected prisoners often lead complex lives and 33 
understanding their journeys through the HCV continuum can inform the development of meaningful HCV 34 
care pathways. Many challenges exist to optimising HCV treatment uptake in this group and incarceration 35 
is an opportunity to successfully engage HCV infected prisoners who underutilise and are underserved by 36 
community-based medical services. Support and linkage to care on release is essential to optimising HCV 37 
management. 38 
 39 
Introduction  40 
High levels of undiagnosed and untreated Hepatitis C Virus (HCV) infection exist in prison populations 41 
globally[1–3]. As a result of the ongoing criminalisation and imprisonment of people who inject drugs 42 
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(PWID), the main risk factor for HCV infection in prisoners is injecting drug use (IDU)[1,2,4]. An estimated 43 
25% of the global prison population has been exposed to HCV[1]. Prison is a critical setting to access HCV 44 
infected PWID and provides an important public health opportunity to manage this epidemic. 45 
HCV screening and treatment in PWID and prisoners is low (9%-12%)[5–7]. Barriers and enablers to 46 
engagement in the HCV care continuum have been identified in both groups[8–10]. Reducing the pool of 47 
HCV infection in both prisoners and PWID requires increasing the proportion engaging in all aspects of the 48 
HCV care cascade and understanding the challenges to screening, linkage to care, treatment and prevention 49 
experienced by those infected. The availability of highly effective and tolerable direct-acting antiviral 50 
(DAA) treatments have made HCV infection curable and have removed many of the barriers associated 51 
with interferon-based treatment regimens [11,12].  52 
Many jurisdictions are scaling up HCV screening and treatment in PWID and prisoners with a view to 53 
achieving the WHO target of eliminating HCV infection as a major public health concern by 54 
2030[11,13,14]. Evidence has demonstrated that “treatment as prevention” in both groups is cost-effective 55 
and an achievable HCV public health strategy[7,15,16]. Studies are reporting near or micro-elimination of 56 
HCV infection in certain communities and prison settings[17–19]. Despite having the tools to cure and 57 
prevent HCV infection and the optimism and enthusiasm brought by these reported successes, many 58 
countries, including Ireland, struggle to expand HCV care to prisoners. There are no Irish prison-based 59 
needle syringe programmes (NSP) but methadone maintenance treatment (MMT) is available at all prison 60 
locations in the Republic of Ireland. 61 
There are over 3,500 persons incarcerated in Ireland on any given day with an annual turnover of over 7,500 62 
unique prisoners[20]. The most recent national estimate of HCV prevalence in Irish prisoners is 13% with 63 
significant inter-prison variation related to levels of PWID incarcerated at the prison location[21]. Recently 64 
published national screening guidelines recommend HCV screening for all prisoners and national HCV 65 
treatment guidelines support the treatment of all HCV infected patients with DAA[22,23]. In-reach 66 
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hepatology services are provided at three of the 12 Irish prisons. The Irish National Hepatitis C Treatment 67 
Programme (NHCTP) have identified prisons as key locations to identify and treat those who have not been 68 
referred to, or engaged with community HCV care[24].  69 
A small number of studies have reported on the lived experience of HCV infected PWID in the 70 
community[25–27]. Previous studies have reported on barriers, enablers and motivators to prisoners’ 71 
engagement with HCV care[28–30]. To our knowledge this is the first study to report on HCV infected 72 
prisoners’ experience of the entire HCV continuum of care, from infection to cure, both in the community 73 
and prison. The study aims to collect and analyse prisoners’ narratives of their HCV journey which will 74 
inform HCV care delivery to this marginalised and underserved group, nationally and internationally. 75 
Materials and Methods  76 
This study is reported according to the Consolidated criteria for Reporting Qualitative research (COREQ). 77 
Ethical approval was obtained from the Mater Ethics Committee as part of the Seek and Treat component 78 
of The European Hep Care Project and supported and endorsed by the Irish Prison Service’s Ethics Review 79 
Committee[31]. 80 
One-to-one, in-person and in-depth semi-structured interviews were conducted in a purposeful sample of 81 
25 prisoners identified as having untreated active HCV infection and offered DAA treatment during their 82 
current prison sentence. Sampling was purposeful aiming to maximise variation in age, country of origin, 83 
liver disease stage, HIV co-infection, stage of treatment including treatment deferral (DAA) and non-84 
completion (interferon-based). Three selected prisoners refused to participate, two due to family visits and 85 
one due to a court appearance. Data was collected from July-November 2018 at Mountjoy Prison, an all-86 
male medium-security prison located in Dublin, Ireland. A data collection tool (table 1 and 2) and interview 87 
guide was designed by the research team and included questions related to all parts of the HCV treatment 88 
cascade including HCV acquisition risks. The interview guide covered the following themes: HCV journey 89 
in the community (risk behaviour, diagnosis and engagement in HCV care), barriers to community HCV 90 
engagement, impact of HCV infection on health and quality of life, description of prison HCV journey 91 
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(both current and previous incarcerations), the experience of treatment, the impact of treatment on health 92 
and wellness, concerns about re-infection and the positives and negatives of prison based HCV care. 93 
Informed consent was sought from interviewees prior to study participation. Participants were assured of 94 
confidentiality, anonymity and the ability to withdraw from the study should they wish. Prisoners were 95 
reassured that refusal to participate or their withdrawal from the study would not impact their medical care. 96 
No financial inducement for study participation was offered. The interviews were conducted by the lead 97 
author DC, in a private consultation room at Mountjoy Prison and lasted an average of 35 minutes each. 98 
DC is the addiction specialist doctor at the study location and was known and provided clinical care to all 99 
the research participants. Demographic data was collected on a standardised data collection form by the 100 
interviewer prior to starting the in-depth interview. Digital recordings of the interviews were made and 101 
were later transcribed verbatim for data analysis and destroyed following transcription. Transcripts were 102 
coded for anonymity and following the removal of any personal identifiers stored on a password-protected 103 
encrypted hard drive. Demographic data was anonymised and uploaded to an encrypted Excel sheet using 104 
Microsoft word. All participant data was stored in accordance with Irish and European data protection laws. 105 
Statistical analysis on collected demographic data was performed using the Statistical Package for Social 106 
Science (verison23). Data is primarily expressed as means (SD) or n (%).  107 
Transcripts were imported into QSR International’s NVivo 11 software (NVivo qualitative data analysis 108 
Software 2012) for coding and thematic analysis following a grounded theory approach [32,33]. This 109 
approach was chosen because prisoners are considered a hard-to-reach population and their experiences of 110 
HCV care are poorly understood and rarely reported in the published literature [34,35].  111 
Thematic coding comprised four stages, data familiarisation, initial low-level indexing of collected data, 112 
second level line-by-line open coding concentrating on the generation of data-driven categories and 113 
subcategories and finally focused coding involving refining and mapping second level codes within and 114 
across categories[33]. The thematic coding was revised with each analysis of the interview transcripts and 115 
data collection and analysis ceased when thematic saturation was achieved (agreed by researcher 1 and 2). 116 
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Illustrative quotes from the interview transcripts supporting the thematic analysis are included and are 117 
reported using an assigned pseudonym and the participant’s age. 118 
Table 1. Description of study participants 119 
 120 
Pseudonym Age Treatment status 
Duane 42 Completed treatment with SVR 
Raymond,  42 Completed treatment with SVR 
Anthony 46 Deferred treatment  
Shane 38 HIV co-infected and completed treatment with SVR  
David 42 On treatment  
Paul 52 Completed treatment with SVR 
Noel 33 Deferred treatment  
Dean 36 Completed treatment awaiting SVR 
Gavin 37 On treatment  
Michael 35 Deferred treatment  
Brendan 59 Completed treatment with SVR 
Nathan 40 HCV co-infected and completed treatment  
Edward 38 On treatment  
Gary 30 Completed treatment with SVR 
Thomas 35 Completed treatment with SVR 
William 38 On treatment  
Patrick 44 Completed and awaiting SVR 
Daniel 41 On treatment  
John 47 HIV co-infected on treatment  
Clint 36 Completed treatment with SVR 
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Kenneth  41 Completed treatment awaiting SVR 
Colm 38 Completed treatment with SVR 
Graham 34 Completed treatment with SVR 
Emmett  41 Completed treatment with SVR 
Leslie 42 On treatment  
 121 
SVR: Sustained virological response (HCV RNA negative 12 weeks post DDA treatment); HCV: 122 
Hepatitis C virus; HIV: Human Immunodeficiency Virus 123 
 124 
Results 125 
A total of 25 male prisoners participated (table 1). The mean age of the study population was 39.5 years. 126 
Participants were incarcerated from an early age (mean=18.3 years), experienced multiple incarcerations 127 
(mean=eight) and spent over a decade in prison (mean=12.5 years). All participants reported a history of 128 
IDU. Two patients were co-infected with HIV infection, 10 had completed treatment with sustained 129 
virological response (SVR), three completed treatment and were awaiting 12-week post-treatment bloods 130 
(i.e. SVR12), seven were on treatment and two had deferred treatment at the time of their interviews.  131 
Two participants had a period of community release during their current sentence (revoked temporary 132 
release (TR)) and their experiences of community release are included in the narratives. All participants 133 
had a history of sharing drug-taking paraphernalia in the community. 72% of the study cohort had a history 134 
of MMT and had spent almost a decade (9.2 years) on this treatment. (Table 2) 135 
Table 2. Demographics of study participants in Mountjoy Prison, Ireland (September 2018) 136 
 
   
Variable Value n Value % Mean (SD) 
Age*     39.5 (6.4) 
Age of first incarceration*   
 
18.3 (6.8) 
Episodes of incarceration*  
 
 8 (2.6) 
Total time incarcerated (years)*  
 
12.5 (5.8) 
8 
 
Age of first drug use*  
 
15. 3 (3.2) 
Age of first Injecting drug use*  
 
 18.5 (3.2) 
 Country of origin       
Ireland 23 92 
 
HCV acquisition risk factors       
History of heroin use  25 100 
 
History of injecting drug use 25 100 
 
Shared needles (syringes) in the community 18 72 
 
Shared equipment (drug taking paraphernalia) in the 
community  
25 100 
 
Shared razor in prison(ever) 2 8 
 
Shared toothbrush in prison(ever) 2 8 
 
Prison tattoo 8 32 
 
Unsterile tattoo community 2 8 
 
Self-declared alcohol use       
Alcohol problem prior to incarceration 8 32 
 
Treatment for alcohol use 1 4 
 
Methadone maintenance treatment (community and 
prison) 
      
Methadone treatment history 18 72 
 
Length of time on methadone maintenance treatment     9.2 (5.8) 
          Values are means (±SD) for continuous variables or n (%) for categorical variables  137 
The following themes emerged from analysis of the data: medical and social factors influencing 138 
engagement in HCV care in the community, adverse impact of HCV on health and wellness, positive 139 
experience of prison life and health care, the transformative clinical and non-clinical changes associated 140 
with HCV treatment and cure and the reality of community release. The study generated a substantive 141 
theory of the need to increase the importance of HCV care among the routine competing priorities 142 
associated with the lives’ of PWID.  143 
 144 
Medical and social factors influencing engagement in community HCV care 145 
Fear of treatment, lack of knowledge, lack of relevance and competing priorities, 146 
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Participants described many barriers to engagement with HCV care in the community. Many had witnessed 147 
friends struggling with historical treatment regimens and a number of those interviewed had discontinued 148 
interferon-based treatment due to the adverse side effects experienced. 149 
 “I’d heard a lot of horror stories about symptoms and all that, side effects”. (Gavin, 37, on treatment) 150 
“The bleeding nightmares and sweats were really, really bad... was on it for a few… a couple of weeks in 151 
2001 and then I just stopped”. (Colm, 38, completed treatment with SVR) 152 
The fear of treatment was linked to a lack of knowledge with many participants still associating treatment 153 
with interferon-based therapies and related side effects. Many described not being aware of the new 154 
treatment options until being offered them in prison and some expected that injections were still needed for 155 
treatment. 156 
“They say knowledge is power. I didn’t know. I thought you had to inject yourself…afraid of the needle 157 
buzz and all that, couldn’t believe it was only a tablet”. (Emmett, 41, completed treatment with SVR) 158 
A consistent theme emerging from prisoners’ memories of their first diagnosis was one of relief when 159 
associated with a negative HIV diagnosis. For co-infected prisoners their HCV diagnosis became irrelevant 160 
when compared to their HIV diagnosis. Most participants were diagnosed with HIV in the late eighties/early 161 
nighties: a time when HIV was potentially a terminal diagnosis and when HCV infection was viewed as the 162 
less serious infection. Many viewed HCV as benign and lacking relevance and did not attribute any physical 163 
or mental health issues to being chronically infected until they had experienced the benefits of treatment.  164 
“I was in there (prison) and I got it (BBV screen) done and it was...the best Christmas present I ever got. 165 
Like I didn’t even mind that I had it... at that stage I was just thinking HIV”. (Kenneth, 41, completed 166 
treatment awaiting SVR) 167 
 168 
All participants describe their periods out of prison as stressful requiring a daily prioritisation of demands. 169 
Active dependence was often the priority demand. The struggle to treat withdrawals and manage cravings 170 
was overwhelming for most and was often the first and most pressing daily demand. While most where 171 
engaged in MMT, active “chaotic” drug use was common. Often re-incarceration was associated with 172 
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criminal activity related to drug use and all participants described a revolving door of release and re-173 
incarceration. 174 
“I was strung out when I came in …They asked me about it (HCV treatment) once or twice but I was, to be 175 
honest... my life was chaotic, I couldn’t manage it”. (William, 38, on treatment) 176 
Adverse impact on health and wellness 177 
Many participants described the negative impact HCV infection had on their physical and mental health. 178 
Symptoms included low energy and mood, fatigue, generalised aches and pains, distended abdomen, poor 179 
sleep and pale or yellow skin pallor. Often the severity of these symptoms was only recognised post-180 
treatment. 181 
“I had no energy, that was one of the main things...I always had low energy. Pains; I used to get pains in 182 
the front of me stomach and in me liver. Sweats; I used to get sweats. My sleep wasn’t great either, it was 183 
on and off. And, I used to go yellow, people would say to me “I’m tanned” or “you’re real yellow”. And it 184 
was like that throughout the years”. (Clint, 36, completed treatment with SVR) 185 
A small number of participants described having a fatalistic view of their illness and continued high-risk 186 
drug taking based on this view. This fatalism was often as a consequence of experiencing family members 187 
or close friends becoming ill or dying of the disease.  188 
“The only reason why I kept on using needles is because I said to myself that in my head, I had it. I had 189 
hepatitis anyway, so it’s not going to make a difference, you know what I mean. I’m going to die- I thought 190 
I was going to die from hepatitis, because my sister died from hepatitis”. (Patrick, 44, completed and 191 
awaiting SVR) 192 
Many also described the stress and fear of transmitting the infection to their sexual partners, family and 193 
social contacts. For some, this prevented them entering long-term relationships. This often exacerbated 194 
existing shame and stigma. 195 
“It affected everything, even relationships when I was with a girl. I never told anybody that I had it, you 196 
know what I mean. And when I’d be with a girl, I’d always wear condoms, and when I was in the 197 
relationship for a while, she would say to me, “you don’t have to use condoms. I know you”. But I never 198 
told her, you know what I mean, I always used them”. (Patrick, 44, completed and awaiting SVR) 199 
 “It’s not something you want to tell your girlfriend that you have, and it’s not something that you want to 200 
pass on to her either... it stresses you out.” (Noel, 33, deferred treatment) 201 
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All study participants described feeling stigma and shame associated with HCV infection. Various terms 202 
were used to illustrate this including: “feeling dirty”, “feeling manky” and “contaminated”. HCV associated 203 
stigma was mainly related to its association with IDU. Often this stigma continued after successful 204 
treatment with SVR since many participants associated being HCV antibody positive with still being 205 
infected and linked to historical IDU. Closely linked with stigma was fear of breach of confidentiality. The 206 
consequence of this fear was that participants only revealed their status to a few people (mainly close family 207 
members) which often reduced their support networks.  208 
“When I was diagnosed with hep C ... I was ashamed ... and then anywhere I’d like deny it (HCV infection) 209 
for a long time. I haven’t got hep C it was just something in the background that was just always there”. 210 
(Gavin, 37, on treatment) 211 
“It’s just something always there like I’m ex addict with hep C, do you know ... like a leper... like some kind 212 
of diseased person”. (Daniel, 41, on treatment)  213 
Interestingly, a number of prisoners described a hierarchy of stigma in prison starting with being a drug 214 
user progressing to a PWID, an HCV infected drug user and finally a HIV infected drug user.  215 
“There should be more education in the prisons about it, for people who don’t need it. Because there is a 216 
stigma to it, you know what I mean. There’s a stigma to someone on gear, but there is a bigger stigma to 217 
someone on gear that used needles...that’s the way, and it’s like, people who use cocaine look down on 218 
someone who uses heroin. People who use heroin look down on someone that’s injecting heroin. Then 219 
people who are injecting heroin with hepatitis c look down on someone who has HIV and it’s just mad”. 220 
(Raymond, 42, completed treatment with SVR) 221 
Many of the study narratives included descriptions of feeling shame and stigma form an early age related 222 
to poverty and social status. No participant described stigma associated with a history of imprisonment as 223 
this was seen as normal within their peer group and the involvement in crime, particularly at any early stage 224 
was to fund the “right” items of clothing and “stuff” that allowed them to “fit in” with their better off peers. 225 
“Been judged and looked down on my whole life. All my life, since being a baby, being looked down you 226 
know? And then I get angry and then the resentment comes in. And I just remember cringing, the cringe, 227 
do you know what I mean? The shame!”. (Michael, 35 deferred treatment) 228 
Positive experience of prison life and health care  229 
The narratives reveal that prison life was often a much-needed break away from the chaos and competing 230 
priorities of their community lives. Incarceration was associated with the distress of being separated from 231 
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loved ones, but also accepted as a normalised pattern of life. Imprisonment often provided prisoners with 232 
much needed stability. 233 
“I lost me Ma and Da and me other brother. Me brother was found ... OD’ed (overdosed) as well, you 234 
know, so it just brought back memories, and I drifted back down, and I start taking crack ... I was selling 235 
gear, and then I start selling crack at night, only getting half an hour sleep for months, and I got caught up 236 
with all the shit and I got locked up you know. This (prison) saved me if I’m being honest”. (Kenneth, 41, 237 
completed treatment awaiting SVR) 238 
All but two of the participants had linked with the in-reach hepatology nurses (specialist nurses who 239 
normally work in a hospital setting but provide HCV treatment at prison-based outpatient clinics). They 240 
describe this relationship as one of trust, familiarity, support and important in their HCV journey. The in-241 
reach nurses where a constant presence over many re-incarcerations. Their level of engagement often 242 
reflected patients’ readiness to consider treatment and types of treatment available at the time. The issue of 243 
drug stability was a major factor during the interferon era with many guidelines and physicians excluding 244 
patients from HCV treatment on the grounds of active drug and alcohol use. The two participants who 245 
deferred treatment cited drug stability as the major factor in their decision. They both were engaging with 246 
addiction services and attempting to stabilise their drug dependence prior to starting HCV treatment. 247 
“Nurses build great relationships with prisoners and you see the nurses up there, they are second to none. 248 
They are brilliant ... She gave me some amount of help up there. They are terrific and have a great rapport 249 
and a great respect”. (Edward, 38, on treatment) 250 
“So, he’s been more or less there from the beginning ... He’s been a good support to me, he doesn’t judge”. 251 
(Nathan, 40, HCV co-infected and completed treatment) 252 
Transformative clinical and non-clinical changes associated with HCV treatment and cure 253 
 254 
Those engaging in or completing treatment found DAA therapies easy to take, tolerable with minimal side 255 
effects. A few described experiencing insomnia and low energy levels in the early stages of treatment which 256 
resolved with basic management (reassurance and advice). The ease in which they completed treatment 257 
exceeded their expectations. 258 
 “The only side effect I had was low energy ... I couldn’t stop sleeping”. (David, 42, on treatment) 259 
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“I was a bit off the first week or two. Stomach cramps and sleep. But it kind of settled and I easily got 260 
through it”. (Gary, 30, completed treatment with SVR) 261 
“A doddle, flew through it…way easier than expected”. (Clint, 36, completed treatment with SVR) 262 
Treatment was associated with increased energy, improved sleep, reduced pain and reduced abdominal 263 
distension. A number of participants reported a change in skin pallor, describing it as “whiter”, “less 264 
yellow” and “rejuvenated”. 265 
“I feel brilliant. All the swelling, I had a lot of swelling in my stomach and it’s all gone down. I’m sleeping 266 
properly; I’m not sweating as much, not getting pains as much. It really helped me”. (Raymond, 42, 267 
completed treatment with SVR) 268 
“I noticed me eyes are white, after whitening up. Me energy, I have loads of energy, I’m doing the gym”. 269 
(Paul, 52, completed treatment with SVR) 270 
Many participants described positive transformative non-clinical outcomes from engagement with HCV 271 
treatment. Participants were visibly moved when speaking about these unexpected changes. Many spoke of 272 
“second chances”, “new beginnings” and “a new start”. These changes included: increased self-esteem, 273 
commitment to living a drug-free lifestyle, increased confidence and self-worth, identity and lifestyle 274 
changes including a reduction in substance misuse. These narratives were presented in the context of 275 
redemption and being grateful for having the opportunity to access the “expensive medication”. 276 
“Like at the moment I’m doing well, I’m off drugs five months, now, I’m drug free, there’s stuff on the 277 
landing and I even turned that down, so I’m happy- I’m after building up me willpower now, it’s a second 278 
chance for me and I can’t fuck it up”. (Duane, 42, completed treatment with SVR) 279 
“I’m finished with drugs. I’ve been clean nearly a year, so I‘ll just be so careful. I even have dreams where 280 
I prick me self with a needle and I’m freaked out when I wake up and I’m sweating…”. (Brendan, 59, 281 
completed treatment with SVR) 282 
Many participants described the hope of social re-inclusion, including performing patient citizenship. They 283 
described the wish to return to work and care and provide for their families. Many hoped that this would be 284 
their last period of incarceration and expressed the need to make up for lost time. 285 
“I have a job there when I get out and all that...and I don’t want to fuck that up…When I’m going to leave 286 
the prison now ...it was like getting the second chance in life to me. So, when I am leaving prison now, I 287 
have plans”. (Thomas, 35, completed treatment with SVR) 288 
“It’s like, that was taken away from me. And it’s like, there’s another chance for it now if you want it, and 289 
I’ve never wanted to get clean as much as I do now, you know what I mean. (Gavin, 37, on treatment) 290 
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A number of participants wished to engage in peer work. They spoke in terms of “giving back”. Some had 291 
benefited from peer workers while undergoing treatment and saw the benefits of this type of support. They 292 
also wanted to dispel the myths of treatment and to share their own positive experiences.  293 
“That’s the whole reason why I’m doing the interview...to help some other people. ‘Hey, this isn’t as bad 294 
as what people make it out to be’ and encourage them to change their life around, just need the right tools.” 295 
(Gary, 30, completed treatment with SVR) 296 
 Reality of community release 297 
Two of the study participants experienced community release during their prison sentence. Both had their 298 
temporary release suspended due to violations of its terms. Both describe a rapid return to high-risk drug 299 
taking and active dependence, mostly triggered by the stress of homelessness. Their narratives illustrate the 300 
lack of community support and structures available to prisoners on release and the complex psycho-social 301 
challenges experienced by both participants and their families. These relapses left them feeling hopeless to 302 
the point of contemplating self-harm. Both welcomed the return to prison and planned to get re-tested to 303 
check for re-infection and re-stabilise their drug use. One of the participants had acquired more criminal 304 
charges and was expecting a further sentence of three to five years. 305 
“It was the homelessness that got me. Not being able to cope out there. There were a couple of times that I 306 
was thinking about harming myself”. (Clint, 36, completed treatment with SVR) 307 
“I had come off everything, got my head together, got out and things didn’t go too well on the outside...can’t 308 
really remember half the things that I was doing, cause I was taking tablets every day of the week and I 309 
ended up on the streets”. (Duane, 42, completed treatment with SVR) 310 
Substantive theory  311 
A grounded theory approach was utilised to produce a substantive theory of the need to increase the 312 
importance of HCV care among the routine competing priorities associated with the lives of PWID [32]. 313 
The collected narratives describe lives characterised by poverty, early school leaving and incarceration 314 
and high-risk opioid dependence associated with ongoing criminality and repeat incarcerations. Active 315 
dependence and homelessness remained the key priorities to manage while in the community and the 316 
relative stability of prison life, with access to trusted health care, increased the priority that prisoners 317 
assigned to their health care needs. Providing increased support to manage these multiple challenges, 318 
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particular at locations where healthcare is delivered, has the potential to increase the priority given to 319 
health and HCV care. Imprisonment offers an opportunity to remove many of these identified challenges 320 
and engage hard-to-reach groups with healthcare. Furthermore, it is important the health care providers 321 
understand the challenges experienced by many socially marginalised groups and adapt a more 322 
understanding and user-friendly approach to how we provide healthcare: a one model approach does not 323 
fit all.   For many HCV infection was still considered a relatively benign illness and treatment with feared 324 
historical treatments was not a consideration either in the community or while incarcerated. The 325 
availability of DAA treatments reduced these historical barriers and re-prioritised HCV care among the 326 
many challenges to be managed by HCV infected prisoners. Understanding and adapting this framework 327 
at a policy and healthcare delivery system level has the potential to improve HCV management. 328 
Expecting HCV infected PWID to engage with HCV care without contextualising it within the broader 329 
challenges of their daily lives is unreasonable. Adapting this framework for healthcare delivery both at an 330 
individual and population level has the potential to improve healthcare access and health outcomes for 331 
this and other marginalised and socially excluded populations.  332 
“I was diagnosed as a teenager … at first I didn’t understand about the consequences or anything… It’s 333 
only hep so I’ll be grand. I was, constantly abusing my body… using and sharing”. (Leslie, 42, on 334 
treatment) 335 
“Because gear (heroin) was my main problem, Gear was my fucking number one problem”. (Brendan, 336 
59, completed treatment with SVR) 337 
“Some of us live a hectic life out there … no homes, off our heads on drugs … robbing, not everyone 338 
would be able to do it (HCV treatment), especially if they are still wrapped up in drugs. For me inside, it 339 
was the perfect opportunity”. (Gavin, 37, on treatment) 340 
“Well it was good because it was a more stable environment (prison) … I was after building a good 341 
relationship with the hospital… and with SJ (hepatology nurse). I was anxious and worried about…side 342 
effects…but there was none whatsoever, it was grand, there wasn’t a bother on me”. (Emmett, 41, 343 
completed treatment with SVR) 344 
Discussion 345 
The study reports unique findings from a qualitative study exploring prisoners’ experiences of their HCV 346 
journey from treatment to cure including: the experience of stigma and shame, the lack of relevance and 347 
importance assigned to HCV infection, competing priorities in the community, stability of prison life, trust 348 
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in the in-reach hepatology services, ease of treatment and transformative clinical and non-clinical outcomes 349 
including increased self-esteem, commitment to living a drug-free lifestyle, increased confidence and self-350 
worth, identity and lifestyle changes with the hope of social re-inclusion.  351 
The barriers of knowledge deficit and fear of treatment described in this study have been reported 352 
previously[8,26]. For the study participants these were now historical since their experience of DAA 353 
treatment was less onerous and simpler than expected. These historical legacies of fear of treatment and its 354 
side effects still prevail and require interventions that increase information among high-risk groups. There 355 
is evidence that prison and community peer workers, in particular, those who have completed treatment, 356 
can increase uptake in HCV care and are seen as credible sources of information by prisoners[36,37]. The 357 
use of peer workers also fits with treated prisoners’ wishes to give back to their communities by sharing 358 
their experiences and encouraging and supporting others to engage with treatment. 359 
The identification of stigma as a major barrier to PWID and prisoners engaging in healthcare, including 360 
HCV care, has been previously reported and was a consistent and repetitive theme across all 361 
narratives[8,10,38]. A number of prisoners who had successfully completed treatment still felt 362 
“contaminated”. The ongoing presence of HCV antibodies, even after treatment, can be confusing and in 363 
general, many cured patients still report having HCV infection[39]. This potentially maintains the stigma 364 
associated with HCV despite the patient successfully completing treatment[26].Using the language of cure 365 
and clearance may have a positive impact on prisoners and enhancing surveillance data to include more 366 
precise serological markers (HCV RNA status) may increase the understanding among those infected and 367 
the general public of the different stages of HCV infection[40]. In the long-term this may reduce the stigma 368 
linked with HCV infection with a greater understanding that being HCV RNA negative is indicative of cure 369 
and the ongoing presence of HCV antibody is historical. The stigma described by these study participants 370 
was not only linked with HCV infection and its association with IDU, it was also linked to poverty and a 371 
lifetime of marginalisation. Repeated incarceration from an early age was characteristic of this study cohort. 372 
Ongoing criminalisation of drug users ensures that this cycle continues and that our prisons remain 373 
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overcrowded with the poorest and most marginalised in society[41–43]. Challenging existing drug policies 374 
of criminalisation and the ineffective “war on drugs”, is critical to tackling communicable diseases in 375 
prisons. At a broader level we need to support a range of public health policies (e.g. access to medical care 376 
including harm reduction services, housing and education) that improve the social and health inequalities 377 
experienced by many marginalised populations including prisoners[43,44]. 378 
It is recognised that in-reach hepatology nurses are a facilitator to HCV treatment both in community and 379 
prison settings [25,45,46]. A positive therapeutic relationship, based on trust and familiarity, increases 380 
treatment uptake and patient’s satisfaction and understanding of treatment[27]. Concerns have been 381 
expressed about how the ease of DAA treatment may erode some of the non-clinical benefits of HCV cure 382 
that were associated with interferon-based therapies[25]. The reduced clinical supervision required for 383 
DAA reduces nurse-patient contact and often eliminates the need to address the psycho-social issues that 384 
characterise prisoners’ lives[25]. This may impact on the therapeutic relationship between patient and 385 
treating nurse and while treatment may achieve HCV elimination, it may not address the other complex 386 
issues that can influence a return to drug use and drug-related risk behaviour. 387 
The narratives collected in this study reveal the complex and overlapping relationship between the 388 
participants’ drug dependence and HCV journeys. All study participants had a history of IDU and all but 389 
one felt they had acquired HCV through the sharing of drug taking paraphernalia. Similar to other studies, 390 
active drug dependence was identified as a barrier to HCV care uptake and when present was prioritised 391 
among the many competing priorities[26,27]. Readiness is seen as an important factor in patient’s decision 392 
to engage in treatment[10]. This concept is closely linked with the cycle of change that underpins many 393 
peoples’ understanding of addictive behaviours and their treatment. [47]. Participants identified that 394 
achieving drug stability was a key priority and when achieved allowed them to contemplate addressing 395 
other issues including HCV care. While participant readiness was identified as a key factor to initiate in 396 
HCV therapy, practitioner support of engaging PWID into HCV-related care and structural support of 397 
PWID receiving access to reimbursed DAA therapies will also be needed to facilitate HCV treatment uptake 398 
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among PWID[48,49]. The stability of prison life and access to addiction treatment, in particular MMT, and 399 
trusted healthcare further facilitated successful engagement in HCV care.  400 
The clinical and non-clinical benefits of HCV treatment have been previously described[16,25,50]. This 401 
study reports similar outcomes including: improved energy, sleep and mood, reduced pain, sweating and 402 
abdominal swelling. These changes were associated with significant non-clinical transformations including 403 
increased self-esteem, self-confidence, sense of identity and a commitment to drug stability and not 404 
returning to prison. Linked with these changes was a hope of social re-inclusion, a return to work, family 405 
and community life and commitment to give back to their community by sharing their experiences to help 406 
others. There is potential to utilise this social capital for HCV prevention and strategy level by engaging 407 
treated prisoners in peer support networks and as recovery ambassadors and coaches (a non-clinical person 408 
who supports others recovering from drug dependence)[51,52]. It is important that expectations are 409 
managed since many challenges will still remain.  410 
This study highlights the difficulty in maintaining stability on release. It is recognised that transition back 411 
to the community post-release is a challenging and high-risk period for prisoners[53–55]. It is also crucial 412 
to the management of HCV with linkage to care, addiction treatment services and harm reduction services 413 
a priority[53,56,57]. Return to homelessness and high-risk drug use characterised the experience of the two 414 
participants who had been released during their present sentence. These findings underscore the need for 415 
support on release and a commitment to addressing the social issues including homelessness experienced 416 
by prisoners released back into the community. 417 
This study generated a substantive theory of increasing the importance of HCV care among the routine 418 
competing priorities associated with the lives of PWID. Reducing the impact of the many medical and 419 
social factors that impact PWID, can change the priority given to healthcare, including HCV treatment, in 420 
their lives[10,26]. This study identified drug dependence and homelessness as priority issues and the 421 
stability of prison life provides the opportunity to address these. Drug dependence, unemployment and 422 
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homelessness have previously been identified as factors that impact negatively on the health and wellness 423 
and ability of PWID and released prisoners to access health care[58,59]. Homeless and marginalised 424 
people’s healthcare usage is characterised by delayed presentations, low usage of primary and preventative 425 
services, high usage of hospital emergency department (ED) and inpatient services and low usage of 426 
hospital outpatient department[60,61]. Recognising the competing priorities in the lives of HCV infected 427 
people should inform policy, health care delivery and HCV management. Providing additional supports 428 
alongside HCV treatment to address these complex needs could improve treatment uptake and outcomes. 429 
Providing HCV treatment at locations were HCV infected people attend for other health and social care 430 
needs (including prisons) could have a further positive impact on HCV management. The management of 431 
psycho-social and other health care needs (including addiction and mental health) often provides the time 432 
and capacity for PWID to manage other health care needs (including HCV care). Increasing the importance 433 
of health care among these challenges has the potential to increase uptake in HCV care. The substantive 434 
theory generated from this study can also inform further research on identifying barriers and facilitators to 435 
HCV screening and treatment uptake among PWID and prisoners.  436 
The strengths of this study are the representativeness of those who participated. The one-to-one 437 
methodology allowed participants to reveal their HCV narratives in a private and confidential forum. A 438 
further strength of this study is the population studied. Prisoners are considered a hard to reach group and 439 
are rarely reported on in the published literature. There are a number of limitations to this study including 440 
the single gender and location of the study design. The interviewer was known to all the prisoners and 441 
provided addiction treatment to them during this or previous sentences. This may have prevented full 442 
disclosure and a biased narrative. Reversely, participants may have provided a more open and honest 443 
narrative to a researcher who was already known to them and who they had an existing therapeutic 444 
relationship with. This study did not analyse differences by treatment category and persons who have yet 445 
to receive treatment might have barriers that were not experienced by persons currently on treatment. 446 
Further research is warranted in this area. 447 
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Conclusion 448 
This study found that HCV infected Irish prisoners are characterised by early age of IDU (18.2 years) with 449 
high levels of needle sharing (72%) and drug paraphernalia sharing (100%). They are incarcerated from an 450 
early age (18.3 years) and experience repeat incarcerations, spending most of their adult lives in prison. 451 
Lifelong competing social and medical factors impact on their ability and willingness to engage in HCV 452 
treatment. The stability of prison life and access to familiar and trusted healthcare, in particular, in-reach 453 
hepatology nurses facilitated engagement with HCV care. Many HCV-infected prisoners have the disease 454 
for over a decade and suffered many associated physical and psychiatric morbidities. These were often only 455 
recognised by their improved wellness on the successful completion of treatment. Prisoners found DAA 456 
treatment easy to manage and describe a range of associated transformative non-clinical outcomes 457 
including: increased self-esteem, increased confidence and self-worth. These changes were often linked to 458 
a commitment to a drug free lifestyle and preventing HCV re-infection. Many expressed a hope of social 459 
re-inclusion including a commitment to engage with peers to educate and support them through treatment. 460 
Prison release is a high-risk and critical time for HCV infected prisoners who return to the competing 461 
priorities of community living. This is often associated with relapse into drug dependence and homelessness 462 
which quickly erodes the benefits achieved while incarcerated. Community support structures for recently 463 
released prisoners are lacking and this high-risk period for overdose deaths and HCV acquisition requires 464 
further research. The relevance of many of the themes identified in this study will reduce with the increasing 465 
commitment to HCV treatment delivery. However, the systemic issues of stigma, marginalisation, social 466 
and health inequalities and ongoing criminalisation of drug users will remain and will require Trojan efforts 467 
by many - including policymakers and politicians - to make meaningful change to those affected. 468 
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